Featured Research

from universities, journals, and other organizations

Antibiotics May Not Be Enough To Stop Recurrent Gastric Lymphoma Caused By Helicobacter Pylori

Date:
August 25, 2005
Source:
American Journal of Pathology
Summary:
Research led by Dr. Anne Mueller at Stanford University School of Medicine demonstrates that successful eradication of Helicobacter may not prevent future aggressive gastric lymphoma since resting B cells are left behind. The paper by Mueller et al., "The role of antigenic drive and tumor-infiltrating accessory cells in the pathogenesis of Helicobacter-induced MALT lymphoma," appears in the September issue of The American Journal of Pathology.

Stanford, CA -- Research led by Dr. Anne Mueller at Stanford UniversitySchool of Medicine demonstrates that successful eradication ofHelicobacter may not prevent future aggressive gastric lymphoma sinceresting B cells are left behind. The paper by Mueller et al., "The roleof antigenic drive and tumor-infiltrating accessory cells in thepathogenesis of Helicobacter-induced MALT lymphoma," appears in theSeptember issue of The American Journal of Pathology.

Helicobacter pylori, a spiral bacterium of the stomach, infects morethan half of the world's population. It is now widely accepted that,aside from gastritis and ulcers, H. pylori is also a causative agent ofgastric lymphoma, specifically gastric B cell lymphoma ofmucosa-associated lymphoid tissue (MALT). While antibiotic treatmenteradicates the bacteria and promotes tumor regression, the effects ofre-infection on disease are more severe.

To address the effects of re-infection and the role of immunecells in disease progression, Dr. Mueller's group used a mouse model ofHelicobacter-induced MALT lymphoma that employs H. felis to mimic humandisease in the mouse. Mice were infected with H. felis and maintainedfor 18 months before being assigned to one of three treatment groups:1) no treatment (primarily infected), 2) antibiotic therapy toeradicate bacteria, or 3) antibiotic therapy followed by re-infection.

As expected, low-grade MALT lymphoma occurred in 35% of allinfected animals. However, frank MALT lymphoma was more prevalent inre-infected animals (44%) than in primarily infected animals (25%).Transcription profiling identified B cell markers in mice that had beeninfected at any point in time, even after successful antibiotictreatment, suggesting that resting B cells remain in the gastricmucosa.

Lymphoid aggregates of re-infected animals also contained moreproliferating cells than those of primarily infected orantibiotic-treated animals (46% vs. 23.2% or 4.8%, respectively).Closer inspection of the lymphoid aggregates revealed that the tumorswere indeed derived from B cells and the main antigen-presenting cellswere follicular dendritic cells. Finally, follicular dendritic cellnumbers were highest in the tumors of re-infected animals followed byprimarily infected and then antibiotic-treated animals, thuscorrelating with severity of gastric lymphoma.

Because it is the follicular dendritic cells that presentantigen to T cells that in turn activate B cell proliferation,follicular dendritic cells appear to be better indicators of tumorbehavior than B cells. Thus, follicular dendritic cells represent anuntapped target in the fight against recurrent gastric lymphoma.

The significance of the described work is that gastriclymphoma progresses more rapidly upon secondary infection. Becauseresting B cells are left behind following antibiotic treatment,re-infection by H. pylori promotes the existing B cells to progressquickly into tumors. Therefore, it is important that treated patientsbe carefully monitored for H. pylori re-infection.

###

Mueller A, O'Rourke J, Chu P, Chu A, Dixon MF, Bouley DM, Lee A,Falkow S: The role of antigenic drive and tumor-infiltrating accessorycells in the pathogenesis of Helicobacter-induced MALT lymphoma. Am JPathol 2005, 167:797-812

Research was supported by the National Institutes of Health(US), the Emmy-Noether-Program of the Deutsche Forschungsgemeinschaft(Germany), and J National Health and Medical Research Council(Australia).

The American Journal of Pathology, the official journal of theAmerican Society for Investigative Pathology (ASIP), seeks to publishhigh-quality original papers on the cellular and molecular mechanismsof disease. The editors accept manuscripts which report importantfindings on disease pathogenesis or basic biological mechanisms thatrelate to disease, without preference for a specific method ofanalysis. High priority is given to studies on human disease andrelevant experimental models using cellular, molecular, biological,animal, chemical and immunological approaches in conjunction withmorphology.


Story Source:

The above story is based on materials provided by American Journal of Pathology. Note: Materials may be edited for content and length.


Cite This Page:

American Journal of Pathology. "Antibiotics May Not Be Enough To Stop Recurrent Gastric Lymphoma Caused By Helicobacter Pylori." ScienceDaily. ScienceDaily, 25 August 2005. <www.sciencedaily.com/releases/2005/08/050825070210.htm>.
American Journal of Pathology. (2005, August 25). Antibiotics May Not Be Enough To Stop Recurrent Gastric Lymphoma Caused By Helicobacter Pylori. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2005/08/050825070210.htm
American Journal of Pathology. "Antibiotics May Not Be Enough To Stop Recurrent Gastric Lymphoma Caused By Helicobacter Pylori." ScienceDaily. www.sciencedaily.com/releases/2005/08/050825070210.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins